Figure 5 from Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine
Year: 2025
Type: other
Abstract: On target silencing and therapeutic implications of TNBC treatment with custom siRictor-NPs. A, Western blot analysis of cells treated with si-NPs (100 nmol/L). Antibodies used are shown on the left of each panel. B, PI(3,4,5)P3 ELISA following in vitro PI3K assay from cells treated with si-NPs (100 nmol/L) or PP242 (500 nmol/L). Each point is the average of 2–3 technical replicates. Midline is average ± SD normalized to the average value of DMSO-treated samples. One-way ANOVA was used. C, CellTiter-Glo assay to measure cell viability in cells treated with a dose curve of si-NP. Each point is the average of 3 biological replicates. Midline is average ± SD normalized to the average value of siControl-NP–treated samples. D, Cells were treated with 200 nmol/L si-NPs, and the proportion of cells in the G2–M cell-cycle phase was assessed by PI staining. Midline is average of 3 biological replicates normalized to the average value of siControl-NP–treated samples. One-way ANOVA was used. E, Annexin V staining to measure cell apoptosis in RICTOR-amplified and RICTOR-diploid cells treated with 200 nmol/L si-NPs. Midline is the average of 3 biological replicates. An unpaired t test was used.
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4408614085